[{"data":1,"prerenderedAt":86},["ShallowReactive",2],{"story-7200-cn":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":19,"questions":20,"relatedArticles":33,"body_color":84,"card_color":85},"7200",null,"口服减肥革命：GLP-1 药丸如何改变医疗治疗","医药创新为医疗保健卖家和健康平台开启新的市场机遇",[],[10,11,12,13,14,15,16,17,18],"https://hips.hearstapps.com/vidthumb/images/fda-building-1634783450.jpg?crop=1.00xw%3A1.00xh%3B0%2C0&resize=810%3A*&quality=70","https://images.mktw.net/im-31158963?width=1260&height=840","https://thehill.com/wp-content/uploads/sites/2/2023/11/654fa389d8b4b1.51861211-e1725045935317.jpeg?strip=1","https://static.biospace.com/dims4/default/984e525/2147483647/strip/true/crop/2121x1194+0+110/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2Fa2%2Fb0%2F503cf465475789a686863705edec%2Fistock-1415584692.jpg","https://images.wsj.net/im-23261007?width=620&height=413","https://assets2.cbsnewsstatic.com/hub/i/r/2025/12/23/78395e39-bc95-42a3-9290-17a22711d0a6/thumbnail/1280x720/7785b032dad174508331663217dc95ea/54f7157e99e612bcbfc4687ec6894630.jpg","https://gray-knoe-prod.gtv-cdn.com/resizer/v2/QYWKGQUG5ZHZ3LNQSLMP4HXVRQ.bmp?auth=3858fc966ea23aaef14e3f89f5d44b57f008fe32047c0e4e9fad471c9a5c094f&width=1200&height=600&smart=true","https://a57.foxnews.com/static.foxnews.com/foxnews.com/content/uploads/2025/12/1280/720/man-pills-in-hand.jpg?ve=1&tl=1","https://imgproxy.divecdn.com/Y96kVdUeD1FyCviPq6qmQvCf3VPLAR_viwm4sEDaouI/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjE5MzA0ODE5LmpwZw==.webp","口服**GLP-1减肥药物**的出现标志着医疗治疗的一个关键时刻，预示着肥胖症和代谢健康管理方式的深刻转变。FDA 批准首个处方口服减肥药，标志着一个关键突破，可能彻底改变患者的可及性和治疗依从性。\n\n**战略市场转型**: 口服替代注射型 GLP-1 药物的推出从根本上改变了体重管理制药领域。临床试验显示出显著的疗效，OASIS 4 试验显示平均体重减轻 16.6%，三分之一的参与者体重减轻超过 20%。这不仅仅是医学进步——它更是一场市场变革，为医疗保健销售商、健康平台和数字健康生态系统创造了前所未有的机遇。\n\n**以患者为中心的创新**: 口服药物形式解决了医疗治疗中的一个关键障碍——患者对注射的抵触情绪。通过将复杂的注射方案转变为简单的每日药丸，制药公司正在使体重管理变得更容易接受，减少畏惧感。这种以患者为中心的方法表明了一种更广泛的趋势，即朝着更方便、更容易获得的医疗干预措施发展，这些措施优先考虑用户体验和治疗依从性。\n\n**生态系统扩张**: 对于电子商务和医疗技术销售商而言，这一发展开辟了多个战略渠道。营养补充剂、健身追踪设备和个性化健康平台等互补产品线现在可以与这种新兴的治疗模式相结合。口服 GLP-1 药物不仅仅是一颗药丸——它是通往更全面、技术赋能的代谢健康管理方法的大门。\n\n长远影响远远超出了减肥的范围。这项创新代表了更广泛的医疗保健趋势的缩影：个性化医疗、技术增强治疗以及向更友好的患者医疗解决方案转变。医疗保健企业家和数字平台不应将其视为单一产品发布，而应视为重新构想如何设计、交付医疗治疗以及将其整合到综合健康生态系统中的邀请。",[21,24,27,30],{"title":22,"answer":23,"author":5,"avatar":5,"time":5},"这种新型口服 GLP-1 药物的减肥潜力有多大？","临床试验结果令人印象深刻，参与者的平均体重减轻了16.6%，并且每三名参与者中就有一人减掉了超过20%的体重。与之前的药物干预相比，这代表了肥胖症治疗的重大进步。",{"title":25,"answer":26,"author":5,"avatar":5,"time":5},"这为医疗保健和健康产品销售商创造了哪些机会？","这项创新开辟了多个市场渠道，包括补充产品线，如营养补充剂、健身追踪设备、个性化健康平台以及可以与新治疗模式整合的数字健康技术。",{"title":28,"answer":29,"author":5,"avatar":5,"time":5},"口服剂型与之前的注射剂型有何不同？","口服药消除了与注射相关的心理和实际障碍，可能提高患者依从性。它将体重管理从复杂医疗程序转变为简单的日常习惯，使治疗更易于获得和更方便。",{"title":31,"answer":32,"author":5,"avatar":5,"time":5},"这种新的减肥药有任何限制吗？","虽然前景看好，但该药物对每个人的效果可能并不相同。个体的代谢反应各不相同，患者应咨询医疗专业人士，以确定个人适用性和潜在副作用。",[34,39,44,48,52,56,60,64,68,72,76,80],{"id":35,"title":36,"source":37,"logo":5,"time":38},139706,"The FDA just approved the first GLP-1 weight-loss pill. Here’s what to know","https://www.detroitnews.com/story/life/wellness/2025/12/23/the-fda-just-approved-the-first-glp-1-weight-loss-pill-heres-what-to-know/87894471007/","3天前",{"id":40,"title":41,"source":42,"logo":5,"time":43},139704,"Arrival of GLP-1 weight-loss pill creates new headache for food, drink makers","https://finance.yahoo.com/news/arrival-glp-1-weight-loss-125534312.html","2天前",{"id":45,"title":46,"source":47,"logo":13,"time":38},139924,"Novo’s Wegovy Pill Wins Obesity Approval, Securing Lead in Oral GLP-1 Race","https://www.biospace.com/fda/novos-wegovy-pill-wins-obesity-approval-securing-lead-in-oral-glp-1-race",{"id":49,"title":50,"source":51,"logo":18,"time":43},139705,"Novo Nordisk’s weight loss pill approved by FDA","https://www.biopharmadive.com/news/novo-nordisk-oral-wegovy-fda-approve-glp-1/808578/",{"id":53,"title":54,"source":55,"logo":5,"time":43},139702,"Wegovy Pill Will Be Available Early Next Year","https://people.com/wegovy-pill-available-early-next-year-11875501",{"id":57,"title":58,"source":59,"logo":15,"time":43},139812,"New weight‑loss pill expected to boost demand for GLP‑1 drugs","https://www.cbsnews.com/miami/video/new-weight-loss-pill-expected-to-boost-demand-for-glp-1-drugs/",{"id":61,"title":62,"source":63,"logo":11,"time":38},139922,"Novo Nordisk first out of the gate with oral weight-loss drug, and its stock jumps","https://www.marketwatch.com/story/novo-nordisk-first-out-of-the-gate-with-oral-weight-loss-drug-and-its-stock-jumps-cd7c97ef?gaa_at=eafs&gaa_n=AWEtsqdpADTyesmru63pBmkCQWW3fomyCn0ljS1fygGrmhgqgFdcxqbcUOm-&gaa_ts=694b33e4&gaa_sig=eqNspEHiOjSFM84sfrzkgFnS429edA6MSl54fLzw6dULg4_-pkaSw5JynsFw7mStxLTypO8MJoF3wXHXl42yAQ%3D%3D",{"id":65,"title":66,"source":67,"logo":17,"time":43},139813,"New Wegovy pill offers needle-free weight loss — but may not work for everyone","https://www.foxnews.com/health/new-wegovy-pill-offers-needle-free-weight-loss-may-not-work-everyone",{"id":69,"title":70,"source":71,"logo":14,"time":38},139923,"Stocks to Watch Tuesday: Novo Nordisk, Huntington Ingalls, ServiceNow","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-12-23-2025/card/stocks-to-watch-tuesday-novo-nordisk-orsted-huntington-ingalls-tp5PYdAqEvf6zQZcdb13?gaa_at=eafs&gaa_n=AWEtsqfZWLaViOzb2SP-9LGzD8Ys_lwvNBkka6jtXis-l6VRaGBhdUSrREa4&gaa_ts=694b33e4&gaa_sig=UJaE8z3A_0h8mhJ3aWu02emPO4c_jLhpOSd8c1x3CE9yUMvqRJK7fuCaToC-t-P2KtNuKZ0aCfrDnoSk0GaG9A%3D%3D",{"id":73,"title":74,"source":75,"logo":10,"time":43},139698,"What to know about new FDA-approved weight loss pill","https://www.wcvb.com/article/what-to-know-about-new-glp-1-weight-loss-pill/69853629",{"id":77,"title":78,"source":79,"logo":12,"time":43},139699,"FDA approves first weight-loss GLP-1 pill","https://thehill.com/newsletters/health-care/5661738-fda-approves-first-weight-loss-glp-1-pill/",{"id":81,"title":82,"source":83,"logo":16,"time":43},139697,"FDA approves new weight loss drug","https://www.knoe.com/2025/12/23/fda-approves-new-weight-loss-drug/","#87025eff","#87025e4d",1766732783985]